STOCK TITAN

Xeris Biopharma Holdings - XERS STOCK NEWS

Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.

Overview

Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical company that specializes in developing and commercializing innovative, ready-to-use biotherapeutics. The company is distinguished by its deep expertise in formulation science and biotherapeutic development, with a unique focus on addressing challenging conditions in the fields of endocrinology, neurology, and gastroenterology. By leveraging proprietary technologies such as XeriSol and XeriJect, Xeris aims to simplify treatment administration and improve patient outcomes through ultra-low volume injectable devices and patient-friendly formulations.

Core Technologies and Product Portfolio

Central to Xeris Biopharma’s mission is the use of breakthrough formulation science. The company’s proprietary technologies have been instrumental in creating products that stand out for their ease of use and direct applicability to clinical needs. XeriSol focuses on innovative formulation strategies while XeriJect has paved the way for ultra-low volume injectable devices that potentially mitigate the discomfort of traditional injection methods. This technological edge supports a portfolio that is uniquely positioned to serve patient populations requiring precise, efficient, and less invasive therapeutic solutions.

Commercial Products

Xeris has successfully brought several therapies to market that address critical conditions with new methods of administration. The product Gvoke offers ready-to-use liquid glucagon, designed for the rapid treatment of severe hypoglycemia, thereby ensuring swift and reliable relief during emergencies. Keveyis, another milestone, is recognized as the first FDA-approved therapy intended for primary periodic paralysis, marking a significant advancement in neuromuscular treatment options. Additionally, Recorlev provides an FDA-approved treatment for endogenous hypercortisolemia in adults with Cushing's Syndrome. Each of these commercial products not only meets specific therapeutic needs but also exemplifies the company’s commitment to refining drug delivery through advanced biotherapeutic formulations.

Innovative Pipeline and Formulation Science

Beyond its existing market offerings, Xeris Biopharma has a robust pipeline of development programs aimed at expanding its footprint in the biotherapeutic landscape. The company’s ongoing research utilizes its own formulation platforms to address unmet clinical needs. By continuously focusing on innovation in drug formulation and injectable delivery, Xeris demonstrates an unwavering commitment to pushing the boundaries of conventional treatment methodologies. Its efforts in refining ultra-low volume, ready-to-use biotherapeutics provide a strategic advantage, potentially alleviating the challenges associated with traditional injection therapies for hundreds of millions of patients.

Market Position and Competitive Landscape

Operating within the competitive arena of biopharmaceuticals, Xeris Biopharma holds a distinct niche due to its focus on patient-friendly, ready-to-use biotherapeutics. Its targeted approach in addressing conditions related to endocrinology, neurology, and gastroenterology distinguishes it from more traditional pharmaceutical companies. Positioned in a sector that demands constant innovation and a careful balance of safety and efficacy, Xeris has integrated rigorous formulation science with practical clinical applications, thus reinforcing its reputation as a company grounded in deep technical expertise and clinical insight.

Patient-Centric Approach and Value Proposition

The company’s innovative approach is underscored by its commitment to enhancing the treatment experience for patients. By developing therapies that are not only clinically effective but also easier to administer, Xeris focuses on lowering the barriers to treatment adherence. The incorporation of patient-friendly injectable devices, designed to ease the discomfort commonly associated with injections, speaks to a broader vision of improved quality of life. This patient-centric perspective is woven into every facet of the company’s operations, ensuring that every product is developed with the end-user’s comfort and convenience in mind.

Operational Excellence and Regulatory Rigor

Xeris Biopharma operates in an environment where compliance and clinical precision are paramount. The company’s products have undergone and continue to meet stringent regulatory standards, assuring stakeholders of both safety and efficacy. Through a disciplined regulatory strategy and a commitment to high-quality manufacturing practices, Xeris reinforces its position as a trusted entity in the formulation and delivery of biotherapeutics. This adherence to strict quality control further enhances the reliability of its products, establishing a strong foundation for long-term credibility in an increasingly competitive field.

Conclusion

In summary, Xeris Biopharma Holdings Inc presents a compelling case study in the integration of advanced formulation science with practical biotherapeutic applications. Its commercial products, such as Gvoke, Keveyis, and Recorlev, exemplify its ability to address diverse patient needs effectively. Supported by proprietary technologies like XeriSol and XeriJect, the company’s approach highlights a strategic blend of innovation, patient focus, and operational rigor. Through its commitment to developing ultra-low volume, ready-to-use therapies, Xeris continues to enhance treatment options within endocrinology, neurology, and gastroenterology, providing a clear reflection of expertise and a steadfast commitment to improved patient outcomes.

Rhea-AI Summary

Xeris Pharmaceuticals has announced a definitive agreement to acquire Strongbridge Biopharma for approximately $267 million, including stock and contingent value rights (CVRs). The transaction values Strongbridge at about $2.72 per share, reflecting a 12.9% premium based on its closing price on May 21, 2021. The deal, unanimously approved by both companies' boards, is expected to close in early Q4 2021. This merger will create Xeris Biopharma Holdings, combining their product portfolios and commercial infrastructures to enhance revenue growth and operational efficiencies in the specialty and rare disease markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (XERS) reported its first quarter 2021 results, highlighting strong financial performance despite pandemic challenges. Gvoke prescriptions exceeded 16,000, marking over 400% growth year-over-year. The company received EU approval for Ogluo and is targeting a Q4 2021 launch. Financially, Gvoke net sales reached $8.1 million, with a net loss of $18.4 million, improved from $29.2 million in the same quarter last year. As of March 31, 2021, Xeris held $135.9 million in cash and equivalents. Management is optimistic about market stability and product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will participate in several virtual events, including:

  • The diaTribe Foundation Musings event on May 13, 2021
  • RBC Capital Markets Global Healthcare Conference on May 19, 2021
  • Jefferies Global Healthcare Conference on June 2, 2021

The presentations are accessible via the Company's website. Xeris focuses on innovative injectable drug formulations and has developed technologies that enhance the ease of use for patients and caregivers, including its Gvoke® product in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
conferences
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will announce its Q1 2021 financial results before the U.S. market opens on May 13, 2021. A conference call will follow at 8:30 a.m. ET for management to discuss the financial and operational outcomes. Xeris is focused on developing innovative, ready-to-use injectable and infusible therapies, leveraging proprietary technologies like XeriSol™ and XeriJect™ to simplify drug administration. The company aims to improve patient experiences while reducing healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
-
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) announced an amendment to its loan agreement with Oxford Finance and Silicon Valley Bank, extending interest-only payments for up to 12 months. This allows the company to defer principal payments of $17.4 million initially due between January and December 2022 to January 2023. The final maturity date of the debt facility is set for June 1, 2024. CEO Paul R. Edick emphasized the flexibility this provides to conserve cash while advancing Gvoke's sales, which treats hypoglycemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) has received approval from the UK’s Medicines and Healthcare Regulatory Agency for Ogluo® (glucagon) injection, indicated for treating severe hypoglycemia in patients aged 2 and above with diabetes. Previously, Ogluo was approved by the European Commission in February 2021. The marketing authorization is recognized in the UK and 27 EU countries. Xeris is actively seeking commercialization partners, aiming for a fourth quarter 2021 launch in select EU regions. Gvoke, a similar product, was FDA-approved in September 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of 15,250 restricted stock units to 10 new employees on March 31, 2021. This action was made under Xeris' Inducement Equity Plan, which incentivizes new hires with equity awards. The stock options will vest over four years, with specific vesting schedules tied to continued employment. Xeris specializes in ready-to-use injectable and infusible drug formulations, aimed at improving patient and healthcare experiences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced a registered direct offering of 6,553,398 shares at $4.12 each, securing gross proceeds of $27 million. The offering, managed without underwriters, is expected to close on March 15, 2021. Proceeds will fund working capital and general corporate purposes, detailed in a forthcoming prospectus supplement. This offering is part of a shelf registration declared effective in August 2019 by the SEC. Xeris focuses on creating ready-to-use injectable therapies leveraging advanced formulation technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.82%
Tags
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported its fourth quarter and full-year 2020 financial results, highlighting continuous growth in Gvoke prescriptions, up 11% quarter-over-quarter and 350% year-over-year. The company secured a positive opinion from the EMA for Ogluo, with expectations for a Q4 2021 launch in select EU countries. Xeris also converted $39.1 million of convertible notes into shares, improving its cash position to $133.8 million. However, the net loss for Q4 2020 was $21.9 million, a decrease from $33.1 million in Q4 2019.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its fourth quarter and full-year 2020 financial results on March 9, 2021, before U.S. markets open. A conference call is scheduled for 8:30 a.m. ET that same day to discuss the results. Xeris specializes in developing ready-to-use injectable and infusible drug formulations, leveraging its proprietary XeriSol™ and XeriJect™ technologies. These innovations aim to simplify medication administration, enhance stability, and reduce costs. For more information, visit www.xerispharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags

FAQ

What is the current stock price of Xeris Biopharma Holdings (XERS)?

The current stock price of Xeris Biopharma Holdings (XERS) is $5.08 as of April 1, 2025.

What is the market cap of Xeris Biopharma Holdings (XERS)?

The market cap of Xeris Biopharma Holdings (XERS) is approximately 784.3M.

What is the primary focus of Xeris Biopharma Holdings?

Xeris Biopharma Holdings is primarily focused on developing and commercializing innovative, ready-to-use biotherapeutics for conditions in endocrinology, neurology, and gastroenterology, using proprietary formulation technologies.

What are the key commercial products offered by Xeris?

The company offers products such as Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

What proprietary technologies underpin Xeris's product development?

Xeris leverages its proprietary formulation platforms, notably XeriSol and XeriJect, which allow for the creation of ultra-low volume, ready-to-use injection therapies that emphasize patient comfort and ease of use.

How does Xeris address the challenges associated with traditional injections?

By focusing on ultra-low volume injectable devices and advanced formulation science, Xeris aims to reduce the discomfort associated with traditional injections, potentially easing treatment for hundreds of millions of patients.

In which therapeutic areas does Xeris operate?

Xeris operates in several therapeutic areas including endocrinology, neurology, and gastroenterology, addressing conditions that benefit from improved biotherapeutic formulations.

What distinguishes Xeris's approach in the biopharmaceutical industry?

Xeris's approach is distinguished by its integration of advanced formulation science with patient-centric delivery methods, ensuring that its therapies are not only clinically effective but also address the practical challenges of medication administration.

How does the company ensure the quality and safety of its products?

The company adheres to strict regulatory standards and employs rigorous quality control measures, ensuring that each product meets the required safety and efficacy benchmarks set by regulatory authorities.

How is Xeris positioned within its competitive landscape?

Xeris is positioned as a niche biopharmaceutical company with a strong focus on innovative biotherapeutics. Its specialized approach to drug formulation and patient-friendly injectable therapies helps differentiate it from traditional companies in the pharmaceutical industry.
Xeris Biopharma Holdings

Nasdaq:XERS

XERS Rankings

XERS Stock Data

784.32M
145.30M
3.99%
42.87%
6.91%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHICAGO